A recent study has thrown a fresh and intriguing light on the potential benefits of systemic therapy for psoriasis, hinting at a significant reduction in the risk of dementia among patients who receive this type of treatment. The research, though preliminary, offers a provocative new perspective on the interaction between autoimmune disorders, systemic inflammation, and cognitive health.
According to the study, patients aged between 65 and 95 with psoriasis who were treated systemically displayed a lower likelihood of developing dementia than their untreated counterparts. Intriguingly, the systemic treatment group also demonstrated a reduced risk relative to the general population—a suggestion that, if substantiated by further research, could have profound implications for our understanding of dementia and its potential prevention.
Autoimmune disorders such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease have long been associated with higher rates of cognitive impairment and dementia. It’s thought that systemic inflammation and pro-inflammatory cytokines like TNF alpha and IL-17 are key culprits, wreaking havoc on the brain. However, the exact processes and pathways remain shrouded in mystery.
The study, which was presented at the Society for Investigative Dermatology (SID) 2025 Annual Meeting, retrospectively analyzed US medical records spanning two decades, from 2004 to 2024. This comprehensive review encompassed data from over 14,000 psoriasis patients on systemic therapies, nearly 40,000 untreated psoriasis patients, and a matched general population group of over 5.77 million individuals.
The adjusted odds ratios (aORs) for different types of dementia in the treated psoriasis group were markedly lower both in comparison to the untreated group and the general population. The findings could herald a paradigm shift in how we view the role of systemic treatments for diseases like psoriasis, hinting at potential additional benefits extending beyond the realm of cutaneous symptoms.
These insights align with a broader trend in biotech, where the interconnectivity between seemingly disparate conditions is increasingly coming to the fore. The understanding that the body is an interconnected ecosystem, where a change in one area can have profound effects elsewhere, is a concept that is rapidly gaining traction.
While it’s important to underscore that this research is still in its early stages and far from altering clinical practice, it certainly adds a new layer to the burgeoning body of evidence linking chronic inflammation to neurodegeneration. As we continue to unravel the complex tapestry of the human body and its myriad of interconnected systems, studies like these underscore the importance of a holistic approach to healthcare, one that takes into account the far-reaching impacts of both disease and treatment.
Read more from medscape.com
